Impact of Diabetes on the Efficacy of Low-Voltage Area Ablation for Persistent Atrial Fibrillation: A Subanalysis of the SUPPRESS-AF Trial.

The interaction term between diabetes status and LVA ablation showed a consistent direction toward attenuation of treatment efficacy in patients with diabetes; however, it did not reach statistical significance after adjustment (hazard ratio for interaction=2.06 [95% CI, 0.94–4.52]; P =0.07), likely reflecting the limited sample size in the diabetic subgroup and the resulting wide 95% CIs (Table S3 ).

also in 111,027 other papers